Alcentra Capital Corp (ABDC) Given Consensus Recommendation of “Hold” by Brokerages

Alcentra Capital Corp (NASDAQ:ABDC) has been assigned an average recommendation of “Hold” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $11.00.

A number of brokerages recently weighed in on ABDC. Raymond James Financial upgraded shares of Alcentra Capital from an “underperform” rating to a “market perform” rating in a report on Thursday, January 11th. UBS upgraded shares of Alcentra Capital from an “underperform” rating to a “market perform” rating in a report on Thursday, January 11th. ValuEngine cut shares of Alcentra Capital from a “strong-buy” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Keefe, Bruyette & Woods set a $7.00 price objective on shares of Alcentra Capital and gave the company a “hold” rating in a report on Thursday, March 15th.

How to Become a New Pot Stock Millionaire

In other news, insider Branko Krmpotic purchased 10,000 shares of the stock in a transaction on Tuesday, March 20th. The stock was bought at an average price of $6.15 per share, for a total transaction of $61,500.00. Following the acquisition, the insider now directly owns 14,000 shares of the company’s stock, valued at approximately $86,100. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired a total of 14,750 shares of company stock valued at $91,788 in the last quarter. 4.96% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Stilwell Value LLC acquired a new position in Alcentra Capital during the 4th quarter worth approximately $8,701,000. Pacific Ridge Capital Partners LLC acquired a new position in Alcentra Capital during the 4th quarter worth approximately $1,171,000. BlackRock Inc. grew its holdings in Alcentra Capital by 18.0% during the 4th quarter. BlackRock Inc. now owns 89,703 shares of the asset manager’s stock worth $753,000 after acquiring an additional 13,669 shares in the last quarter. Wasatch Advisors Inc. grew its holdings in Alcentra Capital by 151.5% during the 4th quarter. Wasatch Advisors Inc. now owns 85,813 shares of the asset manager’s stock worth $720,000 after acquiring an additional 51,689 shares in the last quarter. Finally, Bramshill Investments LLC acquired a new position in Alcentra Capital during the 4th quarter worth approximately $512,000. Institutional investors own 35.19% of the company’s stock.

Shares of ABDC stock opened at $7.16 on Friday. The company has a market capitalization of $101.29, a P/E ratio of 5.42 and a beta of 0.57. Alcentra Capital has a fifty-two week low of $5.93 and a fifty-two week high of $14.73.

Alcentra Capital (NASDAQ:ABDC) last announced its quarterly earnings data on Wednesday, March 14th. The asset manager reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $8.20 million during the quarter, compared to analysts’ expectations of $7.77 million. Alcentra Capital had a negative net margin of 57.28% and a positive return on equity of 10.56%. research analysts expect that Alcentra Capital will post 0.94 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 4th. Shareholders of record on Friday, March 30th were issued a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a yield of 10.06%. The ex-dividend date of this dividend was Wednesday, March 28th. Alcentra Capital’s dividend payout ratio (DPR) is presently 54.55%.

TRADEMARK VIOLATION NOTICE: “Alcentra Capital Corp (ABDC) Given Consensus Recommendation of “Hold” by Brokerages” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3336631/alcentra-capital-corp-abdc-given-consensus-recommendation-of-hold-by-brokerages.html.

Alcentra Capital Company Profile

Alcentra Capital Corporation is a specialty finance company that operates as a non-diversified, closed-end management investment company. The Company operates as a business development company and a regulated investment company. It provides customized debt and equity financing solutions to lower middle-market companies, which are companies having annual earnings, before interest, taxes, depreciation and amortization of between $5 million and $15 million, and/or revenues of between $10 million and $100 million.

Receive News & Ratings for Alcentra Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcentra Capital and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Cantor Fitzgerald Raises Intuitive Surgical  Price Target to $510.00
Cantor Fitzgerald Raises Intuitive Surgical Price Target to $510.00
JPMorgan Chase Boosts UnitedHealth Group  Price Target to $266.00
JPMorgan Chase Boosts UnitedHealth Group Price Target to $266.00
Mizuho Reaffirms “Buy” Rating for QUALCOMM
Mizuho Reaffirms “Buy” Rating for QUALCOMM
Noah  and PJT Partners  Critical Review
Noah and PJT Partners Critical Review
Head-To-Head Analysis: The Meet Group  & Quotient Technology
Head-To-Head Analysis: The Meet Group & Quotient Technology
Mersana Therapeutics  Stock Rating Upgraded by Zacks Investment Research
Mersana Therapeutics Stock Rating Upgraded by Zacks Investment Research


© 2006-2018 Ticker Report. Google+.